Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: The Company manufactures and distributes apparatus, instruments, devices, and consumables for life science research. Its strategy focuses on organic growth, operational improvements, and "tuck-under" acquisitions. A key driver for the period was the September 2009 acquisition of Denville Scientific, Inc., a supplier of molecular biology products.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenues | $26.3 million | $19.1 million |
| Gross Profit | $12.8 million | $9.4 million |
| Gross Margin | 48.6% | 49.3% |
| Operating Income | $3.0 million | $2.4 million |
| Net Income | $2.2 million | $1.8 million |
| Diluted EPS | $0.07 | $0.06 |
| Cash from Operations | $3.1 million | $4.3 million |
| Cash and Equivalents (End of Period) | $17.0 million | $15.9 million |
| Long-Term Debt | $11.8 million | $13.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 37.9% year-over-year. Approximately $5.7 million of this increase was attributable to the Denville Scientific acquisition. Adjusted for currency and excluding Denville, organic revenue growth was 4.3%.
- Margin Compression: Gross margin decreased slightly to 48.6% from 49.3%. Management attributes this to Denville's lower gross margins compared to the Company's historical average. Excluding Denville, the gross margin was 51.7%.
- Expense Increases: Sales and marketing expenses rose 60.5% and General and Administrative (G&A) expenses rose 28.5%, primarily driven by the inclusion of Denville's operating costs and increased stock-based compensation ($0.6 million vs. $0.3 million).
- Currency Impact: A weaker U.S. dollar increased revenues by $0.7 million but resulted in a $0.26 million foreign exchange loss and a $2.1 million translation loss in other comprehensive income.
Outlook, Commentary, and Risks
- Management Commentary: Management views the Denville acquisition as accretive to earnings per share. Organic growth is being driven by new product launches, specifically the KDS Legato 200 and PHD Ultra syringe pumps, and a planned major spectrophotometer launch in Q2 2010.
- Liquidity and Capital: The Company maintains a $20.0 million revolving credit facility with $8.2 million available as of March 31, 2010. Debt outstanding ($11.8 million) is primarily related to the Denville acquisition. Management expects current cash and debt capacity to be sufficient for operations for 12 months and beyond but may need to raise additional capital for significant future acquisitions.
- Restructuring: No restructuring charges were recorded in Q1 2010. Remaining payments from the 2009 restructuring plan are expected to be completed in Q2 2010.
- Risks: Key risks include the ability to successfully integrate acquisitions, fluctuations in foreign exchange rates, the impact of the economic crisis on research funding, and the need to obtain regulatory approvals for new products in regenerative medicine.
Investor Verification Checklist
- Acquisition Integration: Verify the ongoing performance and margin contribution of Denville Scientific relative to pro forma expectations.
- Debt Covenants: Confirm continued compliance with the $20 million credit facility covenants regarding income, debt coverage, and working capital.
- Product Launches: Monitor the commercial success of the new syringe pumps and the upcoming spectrophotometer launch in Q2 2010.
- Foreign Exchange Exposure: Assess the impact of currency fluctuations on future earnings, given significant international operations (approx. 43% of revenue).
- Valuation Allowance: Review the status of the valuation allowance against U.S. deferred tax assets, which may be reversed as taxable income predictability improves.